Cel-Sci Corporation with ticker code (CVM) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 11 and 10 and has a mean target at 10.5. Now with the previous closing price of 2.96 this would indicate that there is a potential upside of 254.7%. The 50 day moving average now sits at 2.64 while the 200 day moving average is 3.35. The market cap for the company is $137m. Visit the company website at: https://cel-sci.com
The potential market cap would be $486m based on the market concensus.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and infectious diseases. The company’s lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 product candidates for the treatment of rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
